Chinoin to Use Money Saved Because of Scrapped Fee for R&D

Hungarian drug maker Chinoin, a unit of sanofi-aventis, will be able to spend an additional HUF 1 billion on R&D because of the elimination of a registration fee for drug company sales representatives, spokesman Istvan Rozsa has announced.

The HUF 5 million-per-rep fee, introduced as part of government austerity measures at the beginning of 2007, was scrapped in June 2008 after Hungary's Constitutional Court ruled it to be unconstitutional.

News Monitoring